Refractory ultra–high-risk Choriocarcinoma achieving complete response to intensive multi-agent and intrathecal chemotherapy and anti–PD-L1 therapy
- DOI
- 10.1016/j.gore.2026.102137
- Published
- 2026-08
- Container
- Gynecologic Oncology Reports
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.gore.2026.102137,
title = {Refractory ultra–high-risk Choriocarcinoma achieving complete response to intensive multi-agent and intrathecal chemotherapy and anti–PD-L1 therapy},
author = {Laura Venegas and Brooke Grant and Ana C. Veneziani and Stephanie Lheureux and Shima Deljoomanesh and Barbara-Ann Millar and Genevieve Bouchard-Fortier and Nazlin Jivraj and Valerie Bowering and Katherine Pulman and Amit M. Oza},
year = {2026},
journal = {Gynecologic Oncology Reports},
doi = {10.1016/j.gore.2026.102137},
url = {https://doi.org/10.1016/j.gore.2026.102137}
}RIS
TY - JOUR TI - Refractory ultra–high-risk Choriocarcinoma achieving complete response to intensive multi-agent and intrathecal chemotherapy and anti–PD-L1 therapy AU - Laura Venegas AU - Brooke Grant AU - Ana C. Veneziani AU - Stephanie Lheureux AU - Shima Deljoomanesh AU - Barbara-Ann Millar AU - Genevieve Bouchard-Fortier AU - Nazlin Jivraj AU - Valerie Bowering AU - Katherine Pulman AU - Amit M. Oza PY - 2026 JO - Gynecologic Oncology Reports DO - 10.1016/j.gore.2026.102137 UR - https://doi.org/10.1016/j.gore.2026.102137 ER -
APA
Venegas, L., Grant, B., Veneziani, A. C., Lheureux, S., Deljoomanesh, S., Millar, B., Bouchard-Fortier, G., Jivraj, N., Bowering, V., Pulman, K., & Oza, A. M. (2026). Refractory ultra–high-risk Choriocarcinoma achieving complete response to intensive multi-agent and intrathecal chemotherapy and anti–PD-L1 therapy. Gynecologic Oncology Reports. https://doi.org/10.1016/j.gore.2026.102137
Source records
- crossref · retrieved 2026-09-27T03:11:24.025Z